These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30565669)

  • 1. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
    Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
    Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Wang Y; Stevenson HS; Edelman DC; Meltzer PS; Barr FG
    Mod Pathol; 2015 Sep; 28(9):1214-24. PubMed ID: 26226845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncovering metabolism in rhabdomyosarcoma.
    Monti E; Fanzani A
    Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
    Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
    Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
    Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
    Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Millino C; Pacchioni B; Celegato B; Bisogno G; Romualdi C; Rosolen A; Lanfranchi G
    BMC Cancer; 2016 Nov; 16(1):886. PubMed ID: 27842508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
    Ramadan F; Fahs A; Ghayad SE; Saab R
    Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
    Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
    J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
    Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
    Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.